Reports Q1 revenue $0.5M, consensus $2.14M. As of March 31, 2023, Morphic had cash, cash equivalents and marketable securities of $421 million, compared to $348 million as of December 31, 2022, with the increase primarily due to a private placement of Morphic’s common stock and pre-funded warrants with certain existing investors that was completed in February 2023. Morphic believes its cash, cash equivalents and marketable securities as of March 31, 2023, will be sufficient to fund operating expenses and capital expenditure requirements into the second half of 2026.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on MORF:
- MORF Jumps after Positive Clinical Data
- Morphic Announces Corporate Highlights and Financial Results for the First Quarter 2023
- Morphic Therapeutic to Host EMERALD-1 Topline Results Call on April 25, 2023
- Morphic price target raised to $56 from $45 at SVB Securities
- Morphic to Present at TD Cowen 43rd Annual Health Care Conference
